Skip to main content

Juluca FDA Approval History

FDA Approved: Yes (First approved November 21, 2017)
Brand name: Juluca
Generic name: dolutegravir and rilpivirine
Dosage form: Tablets
Company: ViiV Healthcare
Treatment for: HIV Infection

Juluca (dolutegravir and rilpivirine) is a single-tablet, two-drug regimen of the approved drugs dolutegravir (Tivicay) and rilpivirine (Edurant) for the maintenance treatment of virologically suppressed HIV-1 infection.

Development timeline for Juluca

DateArticle
Nov 21, 2017Approval FDA Approves Juluca (dolutegravir and rilpivirine) for the Maintenance Treatment of Virologically Suppressed HIV-1 Infection
Jun  1, 2017EU and US Submissions for Single Tablet Combining Dolutegravir and Rilpivirine Priority Review Voucher Submitted in US with Anticipated Target Action Date of 6 Months

See also

Juluca (dolutegravir and rilpivirine) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer